[11C]Raclopride | [11C]NPA | |||
---|---|---|---|---|
Baseline | After Amphetamine | Baseline | After Amphetamine | |
Injected dose (mCi) | 8.4 ± 0.3 | 7.8 ± 0.9 | 8.2 ± 0.3 | 8.4 ± 0.3 |
Specific activity (Ci/mmol) | 1574 ± 476 | 1723 ± 770 | 2270 ± 491 | 2018 ± 520 |
Injected mass (μg) | 2.0 ± 0.7 | 1.9 ± 1.0 | 1.1 ± 0.3 | 1.3 ± 0.3 |
Plasma free fraction (fP, %) | 11.6 ± 3.2 | 11.5 ± 3.1 | 9.3 ± 2.0 | 9.4 ± 2.2 |
Nondisplaceable free fraction (fND, %) | 28.4 ± 5.9 | 30.2 ± 5.5 | 2.9 ± 0.9 | 3.0 ± 0.9 |
Clearance (l/h) | 11.7 ± 5.0 | 12.4 ± 2.9 | 118.5 ± 17.5 | 129.4 ± 25.1 |
Cerebellum VT (ml · cm−3) | 0.41 ± 0.07 | 0.38 ± 0.08* | 3.31 ± 0.77 | 3.20 ± 0.86 |
Plasma amphetamine (0 min, ng · ml−1) | 65.9 ± 12.7 | 73.9 ± 5.4 | ||
Plasma amphetamine (30 min, ng · ml−1) | 61.8 ± 11.2 | 69.7 ± 8.2 | ||
Plasma amphetamine (60 min, ng · ml−1) | 61.1 ± 11.5 | 67.0 ± 8.2 |
↵* p < 0.05, paired t test, baseline compared with postamphetamine condition; plasma amphetamine times are relative to the postamphetamine PET scan.